NOW ENROLLING

KCP-330-024/BGOG-EN5/ENGOT-EN5/SIENDO

A Randomized, Double-blinded, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Participants with Advanced or Recurrent Endometrial Cancer | (Version 5 dated 11Mar2020)



KEY INCLUSION CRITERIA:

- Histological confirmed endometrial cancer of the endometrioid, serous, or undifferentiated type. Carcinosarcoma of the uterus is also allowed.
- Completed a single line of at least 12 weeks of taxane-platinum combination therapy (not including adjuvant or neoadjuvant therapy), and achieved partial or complete remission (PR or CR) according to RECIST version 1.1 for:
  - Primary Stage IV disease, OR
  - At first relapse (i.e., relapse after primary therapy including surgery and/or chemotherapy therapy for Stage I-IV disease).
- Must be able to initiate study drug 5 to 8 weeks after completion of their final dose of chemotherapy.
- ECOG 0-1

KEY EXCLUSION CRITERIA:

- Has any sarcomas, small cell carcinoma with neuroendocrine differentiation, or clear cell carcinomas.
- Being treated with a concurrent cancer therapy or concurrent treatment with an investigational agent or participation in another clinical trial.
- Previous treatment with an exportin 1 (XPO1) inhibitor or with anti-PD1 or anti-PD-L1 immunotherapy (e.g., pembrolizumab).
- Patients who received any systemic anticancer therapy including investigational agents or radiation ≤3 weeks (or ≤5 half-lives of the drug [whichever is shorter]) prior to C1D1.
- Previous malignant disease, except patients with other malignant disease, for which the patient has been disease-free for at least 3 years. Concurrent other malignant disease except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma of the skin.

Karyopharm® Therapeutics

This communication contains information on investigational uses of selinexor. The safety and efficacy of these uses have not been established. This communication is intended for scientific exchange only.